Companies › Syndeio Biosciences
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Other, Psychiatry; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zelquistinel Positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor | GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | Phase 2 | Major Depressive Disorder; Healthy Volunteers in Fed and Fasted State | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07099989 | Zelquistinel | Phase 1 | Healthy Volunteers in Fed and Fasted State | Other | Feb 2026 |
| NCT06547489 | Zelquistinel | Phase 2 | Major Depressive Disorder | Psychiatry | Sep 2027 |
| NCT07115329 | Zelquistinel | Phase 2 | Major Depressive Disorder | Psychiatry | Mar 2028 |
SyneuRx International (Taiwan) Arialys Australia atai Therapeutics Neuren Pharmaceuticals Clear Scientific
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.